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agonistic effects. The reaction products were separated by SDS-
PAGE, followed by Coomassie Blue or silver staining. Treatment
of cartilage explants with HtrA1: Human osteoarthritic cartilage
explants were treated with recombinant HtrA1, with or without
CPII. Conditioned media were assayed for sGAG release by
DMMB. Proteoglycans in the media were precipitated using 1%
cetylpyridinium chloride and subjected to SDS-PAGE followed by
Coomassie Blue or silver staining.
Results: The cartilage proteoglycan aggrecan was identiﬁed
as one of the potential substrates of HtrA1 in the mass
spectrometry-based “degradomics” analysis. Incubation of re-
combinant aggrecan G1-IGD-G2 and IGD constructs with wild-
type HtrA1, but not mutant HtrA1, resulted in distinct cleavage
of these substrates. HtrA1 activity was further enhanced by the
peptide agonist CPII, and inhibited by the HtrA inhibitor Ucf-101.
In addition, recombinant HtrA1 cleaved native human aggrecan in
the presence of the CPII peptide agonist. Treatment of cartilage
explants with recombinant HtrA1 signiﬁcantly increased (p<0.05)
the amount of sGAG released compared to control. Further, the
addition of CPII signiﬁcantly increased (p<0.05) the amount of
sGAG release compared to treatment with HtrA1 alone.
Conclusions: Our data suggest that the collagen type II C-
propeptide may induce proteoglycan catabolism by stimulating
the protease activity of HtrA1. Elevated levels of collagen type
II C-propeptide have been detected in osteoarthritic human ar-
ticular cartilage, due to increased collagen synthesis. Excessive
HtrA1 protease activity in OA cartilage may represent another
contributing factor in OA disease progression.
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Purpose: To evaluate the contribution of visfatin, an adipose
tissue-derived hormone, to the pathophysiology of osteoarthritis
(OA) by examining its role in prostaglandin E2 (PGE2) synthe-
sis and matrix degradation. In an inﬂammatory context, PGE2
synthesis is catalysed by cyclooxygenase type 2 (COX-2) and mi-
crosomal prostaglandin E synthase type 1 (mPGES-1), whereas
NAD+-dependent 15-hydroxy prostaglandin dehydrogenase (15-
PGDH) degrades PGE2.
Methods: The synthesis of visfatin by human chondrocytes
from OA patients, with and without stimulation with interleukin-
1β (IL-1β- 10 ng/ml), was assessed by real-time RT-PCR and
immunoblotting. The effects of visfatin (1 to 10µg/ml) on mPGES-
1, 15-PGDH, PGE2, MMP-3 and MMP-13 expressions by human
OA chondrocytes and by primary mouse articular chondrocytes
were examined by quantitative RT-PCR, immunoblotting and
ELISA. A siRNA strategy was used to assess the inﬂuence
of visfatin on the IL-1β induced release of PGE2. Finally, the
role of IGF-1R in visfatin signalling was studied using primary
chondrocytes from IGF-1R knockout mice (IGF-1R-/-).
Results: (1) Visfatin was constitutively expressed by cultured
human OA chondrocytes. Its expression increased 6-fold in re-
sponse to 10 ng/ml IL-1β (p<0.05).
(2) Visfatin at 1 to 5 µg/ml triggered MMP-3 and MMP-13
mRNA expression (up to 6-fold, p<0.01) by primary mouse
articular chondrocytes. Stimulation with 5 µg/ml visfatin led to a
release of 572 ± 280 ng/ml MMP-3 protein (p<0.05). Visfatin
also induced i) PGE2 release (controls 47 ± 8 versus 141 ± 10
pg/ml when treated with 10 µg/ml visfatin, p<0.05), ii increased
expression of the mPGES-1 (14-fold increase, p<0.01) and iii) a
90% decrease (p<0.05) of the 15-PGDH. Interestingly, 1 ng/ml
IL-1β plus visfatin (1, 2.5 or 5 µg/ml for 24 hours) had additive
effects on PGE2 release (19-fold, 31-fold and 35-fold compared
to IL-β, p<0.05; [1 ng/ml IL-β released 1506 ± 67 pg/ml]).
Moreover, IL-1β dramatically decreased 15-PGDH expression by
95% (p<0.001).
(3) Blocking visfatin expression by siRNA inhibited IL-1β-induced
PGE2 release: triggered the release of (1430 ± 467 pg/ml in
presence of IL-1β (10ng/ml) versus 985 ± 292 pg/ml in presence
of IL-1β + siRNA visfatin, -35%, p<0.01) probably due to a 40%
inhibition of mPGES-1 expression (p<0.01). (4) Visfatin is known
to bind to, and to activate insulin receptor (IR). However, IR is not
considered to be usually present on chondrocytes. We therefore
tested the implication of IGF-1R, a close homologue to IR, in
visfatin signalling. When stimulated with 5 µg/ml visfatin, IGF-
1R-/- chondrocytes unexpectedly exhibited higher PGE2 release
than IGF1R+/+ controls (228 ± 4 compared to 86 ± 29 pg/ml,
p<0.05) which rules out the direct implication of IGF-1R in visfatin
action.
Conclusions: Visfatin triggers the synthesis and the release of
MMP-3 and MMP-13 and induces PGE2 synthesis resulting from
an increase of mPGES-1 and a decrease of 15-PGDH expression
in chondrocytes. We therefore consider that visfatin is a novel
and a potential critical target for OA. In vivo experiments are now
needed to test this hypothesis.
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Purpose: Previous studies (Arthritis Rheum 52:3110-24) showed
that DNA de-methylation at speciﬁc CpG sites in the promoters
was associated with the abnormal synthesis of matrix-degrading
enzymes in human osteoarthritis. However, it is not known
whether DNA de-methylation actually causes the abnormal ex-
pression of the proteases. To demonstrate possible cause-effect
relationships and to study the mechanisms involved in the loss of
DNA methylation requires an in vitro system in which experimen-
tally induced gene induction is correlated with de-methylation at
speciﬁc CpG sites.
Methods: Since monolayer cultures of articular chondrocytes
are an established model to study the induction of the typical
OA proteases by inﬂammatory cytokines, we used this sys-
tem. Healthy chondrocytes were harvested from human femoral
head cartilage after hemi-arthroplasty following a fracture of the
neck of femur. The chondrocytes from each patient were di-
vided into ﬁve groups: non-culture; control culture; culture with
the de-methylating agent 5-aza-deoxycytidine (5-aza-dC) or the
inﬂammatory cytokines IL-1β or TNF-α/oncostatin M. At conﬂu-
ency (4-5 weeks), total RNA and genomic DNA were extracted
simultaneously. Relative mRNA expression was quantiﬁed by
SybrGreen-based real-time PCR and a method for quantifying
the percent of cells with DNA methylation at one speciﬁc CpG
site was developed (Epigenetics 2: 86-95). ELISA was used to
analyze IL-1β in the culture.
Results: Initial non-quantitative experiments conﬁrmed IL-1β -
induced expression of MMP-3 and MMP-13 and also demon-
strated induction of IL-1β by itself, which correlated with loss of
